Inhibition of the high-mobility group box-1 (HMGB1)/TLR4/TRAF6/NF-κB signaling pathway is beneficial for treatments of MI/R injury and acute myocardial infarction (AMI) (Sun et al., 2015; Dong et al., 2018). The gene discussed is TLR4; the disease is myocardial infarction.